Katherine E. Lewis
19Patents
8h-index
36Co-inventors
68Inventor score
Filing activity: Oct 7, 2003 → Sep 11, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7910703B2 | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use | Emerging Cross-Sectional Technologies | 38 | Active |
| US7790862B2 | IL-17 and IL-23 antagonists and methods of using the same | Chemistry; Metallurgy | 34 | Active |
| US8822642B2 | Dimeric fusion proteins and related compositions and methods | Chemistry; Metallurgy | 27 | Active |
| US8333968B2 | Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19 | Emerging Cross-Sectional Technologies | 26 | Active |
| US9765147B2 | Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer | Chemistry; Metallurgy | 17 | Active |
| US8496936B2 | Antagonists of IL-17A, IL-17F, and IL-23P19 | Emerging Cross-Sectional Technologies | 15 | Active |
| US10081681B2 | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors | Chemistry; Metallurgy | 10 | Active |
| US8227579B2 | IL-23 antagonists | Chemistry; Metallurgy | 8 | Active |
| US7291589B2 | Uses of human Zven proteins and polynucleotides | Physics | 6 | Expired |
| US10221244B2 | Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer | Chemistry; Metallurgy | 5 | Active |
| US8992922B2 | Antagonists of IL-17A, IL-17F, and IL-23P19 | Emerging Cross-Sectional Technologies | 5 | Active |
| US11274152B2 | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors | Chemistry; Metallurgy | 3 | Active |
| US10618967B2 | Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer | Chemistry; Metallurgy | 2 | Active |
| US9464134B2 | Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19 | Emerging Cross-Sectional Technologies | 1 | Active |
| US9994634B2 | Use of an IL-17/IL-23 bispecific antibody for treating inflammation | Emerging Cross-Sectional Technologies | 0 | Active |
| US11566076B2 | Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers | Chemistry; Metallurgy | 0 | Active |
| US7592312B2 | Methods of modulating gastrointestinal contractility | Physics | 0 | Active |
| US10562967B2 | Treating inflammation with IL-17/IL-23 bispecific antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US11421034B2 | Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.